Overview
V-Bio Ventures is a Belgian Venture Capital firm specializing in life sciences and biotech. The fund invests primarily in Belgian and European companies developing novel therapeutics, diagnostics, and biotechnology platforms.
As one of the dedicated life sciences VCs in Belgium, V-Bio Ventures operates alongside funds like imec.xpand (deep tech) and PMV (ParticipatieMaatschappij Vlaanderen) (government) to finance the Belgian biotech cluster that generated $97M in funding in 2025.
In the news
- Women’s health needs more than awareness. It needs better research, treatments, and investments. For too long, women’s health research has been confined by the concept of ‘bikini medicine’ — focusing on reproductive organs while overlooking how hormonal changes affect the rest of the body. Perimenopause is a striking example. Despite symptoms affecting nearly every woman at some point in her life, it remains poorly understood, with limited treatment options and persistent misconceptions about hormone replacement therapy. In our
- Today Protealis launches its Ready-to-Sow soybean solution MagNfix. A great step in making Europe more self sufficient, and take control of its own protein needs. Well done team!
- Press news: Protealis Launches Ready-to-Sow Soybean Solution MagNfix™ at Euroseeds 2026 Congress 🗞️ Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces the commercial launch of #MagNfix™, its proprietary ready-to-sow #soybean seed #inoculant. The launch is announced during the #Euroseeds2026 Congress in Valencia, Spain, where Protealis is hosting a MagNfix™ launch cocktail event with seed distributors and industry partners. More on: https://lnkd.in/eXeyECev #MagNfix #soybean
- portfolionews Muna Therapeutics just announced the results of the Ph1 trial with MNA-001, an oral TREM2 modulator. The biomarker-rich trial showed the molecule to be safe, well tolerated and having robust target engagement. The trial showed that age-related markers of microglial and innate immune activity and neuronal stress in elderly volunteers shifted toward the levels seen in younger healthy participants. congratulations to the entire team! https://lnkd.in/eKH-Yt4K
- Dutch only: a great interview with Astrivax Therapeutics CEO Hanne Callewaert. A wide ranging discussion on vaccines, innovation and the ecosystem of drug development in general.
- Vaccins hebben de afgelopen vijftig jaar wereldwijd meer dan 150 miljoen mensenlevens gered. Toch staan ze steeds vaker ter discussie. Volgens Hanne Callewaert, CEO van vaccinproducent AstriVax, zijn vaccins het slachtoffer van hun eigen succes. Omdat veel infectieziektes dankzij vaccinatie vrijwel verdwenen zijn, vergeten we hoe gevaarlijk ze ooit waren. Daardoor zien we vandaag vooral de mogelijke risico's van vaccinatie en verliezen we de voordelen uit het oog. Bekijk Trends Talk op Trends Z of beluister als podcast via je
- Our partner Christina Takke will be speaking at the Wintercircus Ghent. Come see her during the From Lab to Market event. The entire V-Bio Ventures team will be a the Tech x Bio event that same day. Come see us and let's talk! https://lnkd.in/e-yA2xJ2
- Join me at the From Lab to Market Event followed by Tech x Bio at the Wintercircus in Ghent!
Something wrong or missing? Send an update. Fixed within 24 hours.